Cargando…

Long COVID after breakthrough SARS-CoV-2 infection

The post-acute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection—also referred to as Long COVID—have been described, but whether breakthrough SARS-CoV-2 infection (BTI) in vaccinated people results in post-acute sequelae is not clear. In this study, we used the US De...

Descripción completa

Detalles Bibliográficos
Autores principales:	Al-Aly, Ziyad, Bowe, Benjamin, Xie, Yan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group US 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9307472/ https://www.ncbi.nlm.nih.gov/pubmed/35614233 http://dx.doi.org/10.1038/s41591-022-01840-0

Ejemplares similares

Acute and postacute sequelae associated with SARS-CoV-2 reinfection
por: Bowe, Benjamin, et al.
Publicado: (2022)

Diabetes after SARS-CoV-2 infection
por: Al-Aly, Ziyad
Publicado: (2023)

Long-term cardiovascular outcomes of COVID-19
por: Xie, Yan, et al.
Publicado: (2022)

Burdens of post-acute sequelae of COVID-19 by severity of acute infection, demographics and health status
por: Xie, Yan, et al.
Publicado: (2021)

Breakthrough SARS-CoV-2 Infections in Prison after Vaccination
por: Brinkley-Rubinstein, Lauren, et al.
Publicado: (2021)

Immunosuppression and SARS-CoV-2 breakthrough infections
por: Kim, Alfred H J, et al.
Publicado: (2022)

Outcomes Among Patients with Breakthrough SARS-CoV-2 Infection After Vaccination
por: Butt, Adeel A., et al.
Publicado: (2021)

Postacute sequelae of COVID-19 at 2 years
por: Bowe, Benjamin, et al.
Publicado: (2023)

Rate and risk factors for breakthrough SARS-CoV-2 infection after vaccination
por: Butt, Adeel A., et al.
Publicado: (2021)

Breakthrough SARS-CoV-2 Infections after Vaccination in North Carolina
por: Uschner, Diane, et al.
Publicado: (2022)

Molnupiravir and risk of hospital admission or death in adults with covid-19: emulation of a randomized target trial using electronic health records
por: Xie, Yan, et al.
Publicado: (2023)

Nirmatrelvir and risk of hospital admission or death in adults with covid-19: emulation of a randomized target trial using electronic health records
por: Xie, Yan, et al.
Publicado: (2023)

Vaccine Breakthrough Infections with SARS-CoV-2 Variants
por: Hacisuleyman, Ezgi, et al.
Publicado: (2021)

Trends and Correlates of Breakthrough Infections With SARS-CoV-2
por: Yamal, Jose-Miguel, et al.
Publicado: (2022)

Panorama of Breakthrough Infection Caused by SARS-CoV-2: A Review
por: Fan, Qinglu, et al.
Publicado: (2022)

Breakthrough SARS-CoV-2 infections after vaccination: a critical review
por: Mohseni Afshar, Zeinab, et al.
Publicado: (2022)

Antibody titers and breakthrough infections with Omicron SARS-CoV-2
por: Dimeglio, Chloé, et al.
Publicado: (2022)

Sinopharm Vaccine, SARS-CoV-2 Breakthrough Infections and Hemoglobinopathies
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

Resident Factors Associated With Breakthrough SARS-CoV-2 Infections
por: Montoya, Ana, et al.
Publicado: (2023)

Relative infectiousness of SARS-CoV-2 vaccine breakthrough infections, reinfections, and primary infections
por: Abu-Raddad, Laith J., et al.
Publicado: (2022)

Comparative evaluation of clinical manifestations and risk of death in patients admitted to hospital with covid-19 and seasonal influenza: cohort study
por: Xie, Yan, et al.
Publicado: (2020)

Temporal trends of COVID-19 mortality and hospitalisation rates: an observational cohort study from the US Department of Veterans Affairs
por: Cai, Miao, et al.
Publicado: (2021)

Neutralization Titers in Vaccinated Patients with SARS-CoV-2 Delta Breakthrough Infections
por: Zou, Jing, et al.
Publicado: (2022)

Infectiousness of SARS-CoV-2 breakthrough infections and reinfections during the Omicron wave
por: Tan, Sophia T., et al.
Publicado: (2022)

575. Local Experience of Breakthrough SARS-CoV-2 Infections After Full Vaccination
por: Khan, Ahmed A, et al.
Publicado: (2021)

Cross-Variant Neutralizing Serum Activity after SARS-CoV-2 Breakthrough Infections
por: Tober-Lau, Pinkus, et al.
Publicado: (2022)

Unpacking the Implications of SARS-CoV-2 Breakthrough Infections on COVID-19 Vaccination Programs
por: Dzinamarira, Tafadzwa, et al.
Publicado: (2022)

Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine
por: Mizrahi, Barak, et al.
Publicado: (2021)

SARS-CoV-2 vaccine antibody response and breakthrough infection in dialysis
por: Anand, Shuchi, et al.
Publicado: (2021)

How to Deal With Vaccine Breakthrough Infection With SARS-CoV-2 Variants
por: Guo, Ying, et al.
Publicado: (2022)

SARS-CoV-2 antibodies and breakthrough infections in the Virus Watch cohort
por: Aldridge, Robert W., et al.
Publicado: (2022)

Primary and Recall Immune Responses to SARS-CoV-2 in Breakthrough Infection
por: D’Orso, Silvia, et al.
Publicado: (2023)

Risk factors for breakthrough SARS-CoV-2 infection in vaccinated healthcare workers
por: Alishaq, Moza, et al.
Publicado: (2021)

Editorial: SARS-CoV-2 Vaccine Responses and Breakthrough COVID-19
por: Parums, Dinah V.
Publicado: (2021)

Burden of Cause-Specific Mortality Associated With PM(2.5) Air Pollution in the United States
por: Bowe, Benjamin, et al.
Publicado: (2019)

SARS-CoV-2 Breakthrough Infections after introduction of 4 COVID-19 Vaccines, South Korea, 2021
por: Yi, Seonju, et al.
Publicado: (2022)

Emerging vaccine-breakthrough SARS-CoV-2 variants
por: Wang, Rui, et al.
Publicado: (2021)

The magnitude and timing of recalled immunity after breakthrough infection is shaped by SARS-CoV-2 variants
por: Koutsakos, Marios, et al.
Publicado: (2022)

Reinfection and Breakthrough Infection of SARS-CoV-2: An Emerging Challenge That Is Threatening Our World
por: Gao, Lin, et al.
Publicado: (2021)

Effectiveness of COVID-19 vaccine (Covaxin) against breakthrough SARS-CoV-2 infection in India
por: Behera, Priyamadhaba, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vs1jjj0absm24p7ef1sr0simd1